Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Bolt in connection with its acquisition of Tipser
Mandate

Vinge advises Bolt in connection with its acquisition of Tipser

December 02, 2021 IT, Telecommunications and Outsourcing M&A Employment and Benefits

Vinge has advised Bolt, a leading checkout and shopper network company, in connection with its acquisition of Tipser, the Swedish-based tech company enabling commerce on any digital surface, to realize their shared vision of enabling shoppers to check out immediately at the point of discovery.

Building upon Tipser’s technology, Bolt will be leveraging Tipser's turn-key publisher marketplaces, touchless merchant integrations, and headless implementation capabilities to enhance Bolt’s Remote Checkout solution.

Vinge’s team mainly consisted of Johan Larsson and Carl Sander (M&A), Emelie Svensäter Jerntorp and Karin Gynnerstedt (Employment), Henrik Borna (IT), Daniel Daun, Lena Westberg, Alice Clarin and Agaton Lindgren (Corporate).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026